MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gether, U.
Right arrow Articles by Schwartz, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gether, U.
Right arrow Articles by Schwartz, T. W.

Evidence for a common molecular mode of action for chemically distinct nonpeptide antagonists at the neurokinin-1 (substance P) receptor

U Gether, X Emonds-Alt, JC Breliere, T Fujii, D Hagiwara, L Pradier, C Garret, TE Johansen and TW Schwartz

University Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark.

The molecular mechanism of action of three chemically distinct nonpeptide antagonists, SR 140,333, FK 888, and RP 67,580, was compared with that of the previously characterized compound CP 96,345, using a series of chimeric constructs between their common target, the rat neurokinin (NK)-1 (substance P) receptor, and the homologous nonresponsive NK-3 (NKB) receptor. The ability of all four nonpeptide compounds to displace radiolabeled substance P from the NK-1 receptor and their ability to inhibit the peptide-induced increase in inositol phosphate turnover were critically dependent on structural elements located in an area from the middle of the second extracellular loop through transmembrane segments V and VI to the middle of the third extracellular loop of the NK-1 receptor. Dissection of the domain around the outer part of transmembrane segments V and VI into smaller segments demonstrated that the individual nonpeptide antagonists, in agreement with their distinct chemical structures, were dependent on different subepitopes within the common putative binding domain. Full NK-1-like susceptibility to SR 140,333, FK 888, and CP 96,345 could be transferred to the NK-3 receptor by exchange of transmembrane segments V and VI and adjacent parts with corresponding segments from the NK-1 receptor. For SR 140,333 and CP 96,345, almost the same effect could be achieved by transfer of two discontinuous segments around the top of transmembrane segments V and VI. RP 67,580 shared interaction sites with the other compounds around the top of transmembrane segment VI but appeared also to be dependent on transmembrane segment VII. It is concluded that four nonpeptide antagonists, despite overt chemical differences, appear to block NK-1 receptor function by interacting in distinct ways with a common site located spatially around the outer part of transmembrane segment VI.

Volume 45, Issue 3, pp. 500-508, 03/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Endocr. Rev.Home page
U. Gether
Uncovering Molecular Mechanisms Involved in Activation of G Protein-Coupled Receptors
Endocr. Rev., February 1, 2000; 21(1): 90 - 113.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
A. R. Renzetti, R.-M. Catalioto, M. Criscuoli, P. Cucchi, C. Ferrer, A. Giolitti, M. Guelfi, L. Rotondaro, F. J. Warner, and C. A. Maggi
Relevance of Aromatic Residues in Transmembrane Segments V to VII for Binding of Peptide and Nonpeptide Antagonists to the Human Tachykinin NK2 Receptor
J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 487 - 495.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
B. Holst, S. Zoffmann, C. E. Elling, S. A. Hjorth, and T. W. Schwartz
Steric Hindrance Mutagenesis versus Alanine Scan in Mapping of Ligand Binding Sites in the Tachykinin NK1 Receptor
Mol. Pharmacol., January 1, 1998; 53(1): 166 - 175.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. L. Roth, M. Shoham, M. S. Choudhary, and N. Khan
Identification of Conserved Aromatic Residues Essential for Agonist Binding and Second Messenger Production at 5-Hydroxytryptamine2A Receptors
Mol. Pharmacol., August 1, 1997; 52(2): 259 - 266.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
S. Perlman, C. M. Costa-Neto, A. A. Miyakawa, H. T. Schambye, S. A. Hjorth, A. C. M. Paiva, R. A. Rivero, W. J. Greenlee, and T. W. Schwartz
Dual Agonistic and Antagonistic Property of Nonpeptide Angiotensin AT1 Ligands: Susceptibility to Receptor Mutations
Mol. Pharmacol., February 1, 1997; 51(2): 301 - 311.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Perlman, H. T. Schambye, R. A. Rivero, W. J. Greenlee, S. A. Hjorth, and T. W. Schwartz
Non-peptide Angiotensin Agonist
J. Biol. Chem., January 27, 1995; 270(4): 1493 - 1496.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y.-M. Li, M. Marnerakis, E. R. Stimson, and J. E. Maggio
Mapping Peptide-binding Domains of the Substance P (NK-1) Receptor from P388D(1) Cells with Photolabile Agonists
J. Biol. Chem., January 20, 1995; 270(3): 1213 - 1220.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1994 by the American Society for Pharmacology and Experimental Therapeutics